Summit Therapeutics (SMMT) is down -9.4%, or -$2.52 to $24.45.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics falls -6.9%
- Akeso says ivonescimab met overall survival endpoint in final anlysis
- Summit Therapeutics price target raised to $50 from $44 at H.C. Wainwright
- Summit Therapeutics’ Ivonescimab: A Promising Competitor to Keytruda with Increased Approval Probability and Price Target
- Summit Therapeutics put volume heavy and directionally bearish